A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC
Clinical trial NCT05519865 · COMPLETED
Trial details
- NCT number
- NCT05519865
- Sponsor
- Chipscreen Biosciences, Ltd.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-26
- Primary completion
- 2024-11-18
- Enrollment
- 118
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.